SEC Form 6-K filed by Immutep Limited

$IMMP
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $IMMP alert in real time by email
6-K 1 d936071d6k.htm 6-K 6-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 6-K

 

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Date as March 25, 2025

Commission File Number 001-35428

 

 

IMMUTEP LIMITED

(Exact Name as Specified in its Charter)

 

 

N/A

(Translation of Registrant’s Name)

Level 32, Australia Square

264 George Street, Sydney

NSW 2000, Australia

(Address of principal executive office)

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒   Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes ☐   No ☒

If “Yes” is marked, indicated below the file number assigned to the registrant in connection with Rule 12g3-2(b): Not applicable.

 

 

 



SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: March 25, 2025

 

IMMUTEP LIMITED
By:  

/s/ Marc Voigt

Name:   Marc Voigt
Title:   Chief Executive Officer
Get the next $IMMP alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$IMMP

DatePrice TargetRatingAnalyst
5/17/2024$10.00Overweight
CapitalOne
8/3/2023$7.00Outperform
Robert W. Baird
8/3/2021$8.30Buy
Ladenburg Thalmann
7/16/2021$8.00Buy
Maxim Group
More analyst ratings

$IMMP
Press Releases

Fastest customizable press release news feed in the world

See more
  • First Patient Dosed in Immutep's TACTI-004 Phase III Trial in First Line Non-Small Cell Lung Cancer

    First patient safely dosed at Calvary Mater Newcastle Hospital in Australia, marking a significant milestone for ImmutepGlobal Phase III with efti will enrol approximately 756 patients at more than 150 clinical sitesTrial results will inform potential marketing approval application in non-small cell lung cancer, one of the largest indications in oncology  SYDNEY, AUSTRALIA, March 25, 2025 (GLOBE NEWSWIRE) --  Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces the first patient has been successfully dosed in the Company's pivotal TACTI-004 Phase III trial. TACTI-004 will evalua

    $IMMP
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Immutep to Present Pivotal TACTI-004 Trial in Progress Poster at the European Lung Cancer Congress 2025

    SYDNEY, AUSTRALIA, March 20, 2025 (GLOBE NEWSWIRE) --  Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces an upcoming poster presentation for the pivotal TACTI-004 Phase III trial. The poster will be presented at the European Lung Cancer Congress (ELCC) 2025, taking place in Paris, France, from 26-29 March 2025. The Trial in Progress poster includes an overview and study design of the TACTI-004 Phase III evaluating the Company's MHC Class II agonist, eftilagimod alfa (efti) in combination with MSD's (Merck & Co., Inc., Rahway, NJ, USA) anti-PD-1 KEYTRUDA® (pembrolizumab) and ch

    $IMMP
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Immutep Quarterly Activities Report Q2 FY25

    Media Release Marking Immutep's transition to a Phase III biotech, the Company's pivotal TACTI-004 trial in first-line non-small cell lung cancer (1L NSCLC) received first regulatory approvalMature data from INSIGHT-003 in 1L NSCLC demonstrates an excellent 32.9-month median overall survival (OS) and 81.0% 24-month OS rate, significantly outperforming historical controlsPromising new results in first line head & neck cancer with PD-L1 CPS <1 reported at ESMO IO 2024, with median OS not reached and 67% 12-month OS rate well above historical controlsPhase II in soft tissue sarcoma shows three-fold increase in tumour hyalinization (trial's primary endpoint, also associated with survival) compa

    $IMMP
    Biotechnology: Pharmaceutical Preparations
    Health Care

$IMMP
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$IMMP
SEC Filings

See more

$IMMP
Leadership Updates

Live Leadership Updates

See more
  • Immutep Appoints Leading Research Institute to Conduct First-in-Human Phase I Study of IMP761

    Media Release Centre for Human Drug Research (CHDR) will conduct Phase I trial to evaluate IMP761, a first-in-class LAG-3 agonist antibody designed to restore balance to the immune system and address the underlying cause of autoimmune diseasesCHDR will utilize its unique challenge model that enables insights into IMP761's pharmacological activity early in clinical developmentTrial expected to begin mid-CY2024 SYDNEY, AUSTRALIA, April 18, 2024 (GLOBE NEWSWIRE) -- Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces it has entered into an agreem

    $IMMP
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Immutep Selects Charles River Laboratories for IMP761's GLP Toxicology Study

    Media Release Appointment of Charles River Laboratories ("Charles River") to run Immutep's preclinical toxicology study evaluating the safety and toxicity of IMP761Forms a key step prior to first-in-human trials for this first-in-class LAG-3 agonist antibody designed to treat the underlying cause of multiple autoimmune diseasesCharles River is a highly respected, global provider of drug discovery and non-clinical development solutions operating more than 110 sites across more than 20 countries SYDNEY, AUSTRALIA, May 29, 2023 (GLOBE NEWSWIRE) -- Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a clinical-stage biotechnology company developing novel LA

    $IMMP
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Immutep Quarterly Activities Report

    Media Release Initiation of integrated Phase II/III AIPAC-003 trial evaluating eftilagimod alpha (efti) and paclitaxel in HER2-neg/low metastatic breast cancer and triple-negative breast cancerPositive final data reported from patients with 2nd line non-small cell lung cancer refractory to anti-PD-(L)1 therapies, including Overall Survival rate of 39% at 21 monthsRandomised TACTI-003 Phase IIb trial has reached 75% enrolment subsequent to quarter end and top line results anticipated in H2 of CY2023Expansion of INSIGHT-003 evaluating triple combination of efti, pembrolizumab and chemotherapy post encouraging initial safety and efficacy in 1st line non-small cell lung cancerSolid cash pos

    $IMMP
    Biotechnology: Pharmaceutical Preparations
    Health Care

$IMMP
Financials

Live finance-specific insights

See more
  • Immutep's Efti in Combination with KEYTRUDA® Generates Excellent Overall Survival Benefit in Patients with Metastatic Non-Small Cell Lung Cancer

    Media Release Median Overall Survival reaches 35.5 months in first-line treatment of metastatic non-small cell lung cancer patients expressing PD-L1 (TPS >1%), 23.4 months in patients with low PD-L1 expression (TPS 1-49%), and has not been reached in patients with high PD-L1 expression (TPS >50%), exceeding expectationsPromising Overall Survival, Overall Response Rate, Progression Free Survival, and Duration of Response visible across all PD-L1 subgroups (TPS <1%, ≥1%, 1-49%, and ≥50%), differentiates efti in combination with KEYTRUDA® from other chemotherapy-free immuno-oncology combinations in non-small cell lung cancerExceptional durability and quality of responses exhibited through ove

    $IMMP
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Immutep Announces Publication of Abstracts at ESMO Congress 2023

    Media Release New updated data from TACTI-002, including more mature Overall Survival data, will be presented during the Mini Oral session on Saturday, October 21st, at 9:05 CESTImmutep to host webcast to discuss ESMO 2023 clinical data on Monday, October 23rd, at 8AM AEDT (Sunday, October 22nd, at 5PM ET) SYDNEY, AUSTRALIA, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces the publication of abstracts with data from the TACTI-002 and INSIGHT-003 trials in 1st line non-small cell lung cancer (1L NSCLC) at t

    $IMMP
    Biotechnology: Pharmaceutical Preparations
    Health Care

$IMMP
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more